Voyager Therapeutics shares data from preclinical programmes for Alzheimer’s treatment
Betsy Goodfellow | February 21, 2024 | News story | Research and Development | Alzheimer's, Neurology, Voyager Therapeutics, preclinical
Voyager Therapeutics has announced new data from is two preclinical programmes targeting pathological tau for the treatment of Alzheimer’s disease (AD).
It is expected that data on VY-TAU01, the company’s lead anti-tau antibody candidate, and its tau silencing gene therapy programme will be presented at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2024), from 5-9 March 2024, in Lisbon, Portugal.
The tau silencing gene therapy programme covers intravenous administration of BBB-penetrant AAV containing primary artificial microRNA targeting tau, and appears to reduce tau broadly and robustly in hTau mouse brains.
The data around VY-TAU01 considers the pharmacokinetics and tolerability of the candidate, for the treatment of Alzheimer’s disease, testing this in mouse and non-human primates.
Todd Carter PhD, chief scientific officer of Voyager Therapeutics, commented: “The Voyager team is increasingly excited about the potential for treatments targeting pathological tau to play an important role in improving clinical outcomes for patients suffering with Alzheimer’s disease. Recent third-party data with tau-targeted investigational therapies have demonstrated reduced spread of pathological tau, as measured by tau PET imaging, and favorable trends in cognition. We look forward to continuing to advance our two programs targeting tau, and observing anticipated data read-outs from others in this space that will play an important role in further validating this target.”
Betsy Goodfellow
Related Content
Lilly’s drug for early Alzheimer’s shows promising results
Eli Lilly (Lilly) has announced positive new data from the long-term extension of its phase …
Eli Lilly’s Kisunla approved by FDA for Alzheimer’s treatment
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Kisunla …
FDA accepts Eisai’s Leqembi sBLA for early AD treatment
Eisai and Biogen have announced that the US Food and Drug Administration (FDA) has accepted …
